Cover Image
市場調查報告書

慢性骨髓性白血病 (CML)

Chronic Myeloid Leukemia (CML)

出版商 Datamonitor Healthcare 商品編碼 603923
出版日期 內容資訊 英文 208 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
慢性骨髓性白血病 (CML) Chronic Myeloid Leukemia (CML)
出版日期: 2017年12月07日 內容資訊: 英文 208 Pages
簡介

本報告提供慢性骨髓性白血病 (CML) 市場相關調查分析,市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等,提供著有系統的資訊。

預測:慢性骨髓性白血病 (CML) (2017年12月7日出版)

  • 摘要整理
  • 市場概要·趨勢
  • 市場定義·調查手法
  • ASCIMINIB
  • BOSULIF (BOSUTINIB)
  • GLEEVEC (IMATINIB)
  • ICLUSIG (PONATINIB)
  • SPRYCEL (DASATINIB)
  • SYNRIBO (OMACETAXINE MEPESUCCINATE)
  • TASIGNA (NILOTINIB)
  • 一次調查手法

治療:慢性骨髓性白血病 (CML) (2017年11月8日出版)

  • 摘要整理
  • 一次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 處方趨勢

流行病學:美國·日本·EU5個國家的慢性骨髓性白血病 (CML) (2017年11月8日出版)

  • 摘要整理
  • 疾病的背景
  • 調查來源·調查手法
  • 預測
  • 流行病學者的考察
  • 優勢與限制
  • 參考文獻
  • 附錄

上市藥:慢性骨髓性白血病 (CML) (2017年12月7日出版)

  • 摘要整理
  • 產品概要
  • 產品簡介:BOSULIF
  • 產品簡介:GLEEVEC
  • 產品簡介:ICLUSIG
  • 產品簡介:SPRYCEL
  • 產品簡介:SYNRIBO
  • 產品簡介:TASIGNA

開發平台:慢性骨髓性白血病 (CML) (2017年12月7日出版)

  • 摘要整理
  • 臨床開發平台概要
  • 產品簡介 (後期) :ASCIMINIB
目錄
Product Code: DMKC5889

Disease Overview

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a myeloproliferative disorder characterized by a single cytogenetic hallmark: the chromosomal translocation t(9;22)(q34;q11), known as the Philadelphia (Ph) chromosome. In a small minority of patients who exhibit the characteristics of CML, the Ph chromosome cannot be detected - this is referred to as Ph-negative CML, or atypical CML.

Market Snapshot

  • The CML market will experience a short period of growth followed by a decline in sales due to the onset of generic competition.
  • The largest unmet needs in CML are overcoming TKI resistance and addressing patients with accelerated or blast phase disease.
  • The number of incident chronic myeloid leukemia cases is expected to increase by 25% over the next 20 years.
  • Generic imatinib will dominate first-line treatment as Sprycel and Tasigna compete for market share in the second line.
  • Asciminib is currently the primary candidate in the pipeline, and may benefit patients progressing on available TKIs.

TABLE OF CONTENTS

FORECAST: CHRONIC MYELOID LEUKEMIA (Published on 07 December 2017)

  • EXECUTIVE SUMMARY
  • MARKET OVERVIEW AND TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • ASCIMINIB
  • BOSULIF (BOSUTINIB)
  • GLEEVEC (IMATINIB)
  • ICLUSIG (PONATINIB)
  • SPRYCEL (DASATINIB)
  • SYNRIBO (OMACETAXINE MEPESUCCINATE)
  • TASIGNA (NILOTINIB)
  • PRIMARY RESEARCH METHODOLOGY

TREATMENT: CHRONIC MYELOID LEUKEMIA (Published on 08 November 2017)

  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: CHRONIC MYELOID LEUKEMIA IN THE US, JAPAN, AND 5EU (Published on 08 November 2017)

  • EXECUTIVE SUMMARY
  • DISEASE BACKGROUND
  • SOURCES AND METHODOLOGY
  • FORECAST
  • EPIDEMIOLOGIST INSIGHT
  • STRENGTHS AND LIMITATIONS
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: CHRONIC MYELOID LEUKEMIA (Published on 07 December 2017)

  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: BOSULIF
  • PRODUCT PROFILE: GLEEVEC
  • PRODUCT PROFILE: ICLUSIG
  • PRODUCT PROFILE: SPRYCEL
  • PRODUCT PROFILE: SYNRIBO
  • PRODUCT PROFILE: TASIGNA

PIPELINE: CHRONIC MYELOID LEUKEMIA (Published on 07 December 2017)

  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • COMPARATOR THERAPY
  • PRODUCT PROFILE (LATE STAGE): ASCIMINIB

LIST OF FIGURES

  • Figure 1: CML market value in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 2: Sales of tyrosine kinase inhibitors in CML, by brand, 2016-25
  • Figure 3: Proportion of drug-treated CML patients receiving branded versus generic products, 2016-25
  • Figure 4: Patient-based forecast methodology for CML
  • Figure 5: Price sources and calculations, by country
  • Figure 6: Asciminib sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 7: Bosulif sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 8: Gleevec sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 9: Iclusig sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 10: Sprycel sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 11: Synribo sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 12: Tasigna sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 13: Distribution of prevalent CML cases according to phase, by country
  • Figure 14: Average proportion of CML patients receiving each treatment type, by phase and line of therapy
  • Figure 15: Top three first-line systemic therapy regimens for chronic-phase CML, by country
  • Figure 16: Top three second-line systemic therapy regimens for chronic-phase CML, by country
  • Figure 17: Top three third-line systemic therapy regimens for chronic-phase CML, by country
  • Figure 18: Top three first-line systemic therapy regimens for accelerated-phase CML, by country
  • Figure 19: Top three first-line systemic therapy regimens for blast-phase CML, by country
  • Figure 20: Proportion of CML patients receiving standard- or high-dose TKI therapy, by phase and line of therapy
  • Figure 21: Top three second-line systemic therapy regimens for accelerated-phase CML, by country
  • Figure 22: Top three second-line systemic therapy regimens for blast-phase CML, by country
  • Figure 23: Top three third-line systemic therapy regimens for accelerated-phase CML, by country
  • Figure 24: Top three third-line systemic therapy regimens for blast-phase CML, by country
  • Figure 25: Trends in incident cases of CML in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 26: Absolute change in incident cases of CML in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 27: Bosulif for CML - SWOT analysis
  • Figure 28: Datamonitor Healthcare's drug assessment summary of Bosulif for CML
  • Figure 29: Datamonitor Healthcare's drug assessment summary of Bosulif for CML
  • Figure 30: Gleevec for CML - SWOT analysis
  • Figure 31: Datamonitor Healthcare's drug assessment summary of Gleevec for CML
  • Figure 32: Datamonitor Healthcare's drug assessment summary of Gleevec for CML
  • Figure 33: Iclusig for CML - SWOT analysis
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Iclusig for CML
  • Figure 35: Datamonitor Healthcare's drug assessment summary of Iclusig for CML
  • Figure 36: Sprycel for CML - SWOT analysis
  • Figure 37: Datamonitor Healthcare's drug assessment summary of Sprycel for CML
  • Figure 38: Datamonitor Healthcare's drug assessment summary of Sprycel for CML
  • Figure 39: Synribo for CML - SWOT analysis
  • Figure 40: Datamonitor Healthcare's drug assessment summary of Synribo for CML
  • Figure 41: Datamonitor Healthcare's drug assessment summary of Synribo for CML
  • Figure 42: Tasigna for CML - SWOT analysis
  • Figure 43: Datamonitor Healthcare's drug assessment summary of Tasigna for CML
  • Figure 44: Datamonitor Healthcare's drug assessment summary of Tasigna for CML
  • Figure 45: Asciminib for CML - SWOT analysis
  • Figure 46: Datamonitor Healthcare's drug assessment summary of asciminib for CML
  • Figure 47: Datamonitor Healthcare's drug assessment summary of asciminib for CML

LIST OF TABLES

  • Table 1: CML market value in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 2: Sales of tyrosine kinase inhibitors in CML, by brand ($m), 2016-25
  • Table 3: Summary of drug classes and molecules in Datamonitor Healthcare's CML forecast, 2016-25
  • Table 4: Exchange rates used for calculating prices
  • Table 5: Patent expiry dates for key marketed brands in CML in the US, Japan, and five major EU markets, by region, 2016-25
  • Table 6: Estimated launch dates of key pipeline products and marketed brands in CML in the US, Japan, and five major EU markets, by region, 2016-25
  • Table 7: Asciminib sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 8: Asciminib patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 9: Bosulif sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 10: Bosulif patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 11: Gleevec sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 12: Gleevec patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 13: Iclusig sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 14: Iclusig patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 15: Sprycel sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 16: Sprycel patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 17: Synribo sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 18: Synribo patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 19: Tasigna sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 20: Tasigna patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
  • Table 21: Hematologists and hematologist-oncologists surveyed for the CML primary research study, 2016
  • Table 22: Hematologists and hematologist-oncologists surveyed for the CML primary research study, 2016
  • Table 23: Commonly used prognostic systems in CML
  • Table 24: Datamonitor Healthcare's classification of CML by phase
  • Table 25: Leading brands for the treatment of CML
  • Table 26: CML phases defined by the WHO
  • Table 27: Cancer registry databases used as a source of CML incidence data, by country
  • Table 28: Forecasting methodology for CML incidence, by country, age group, and gender
  • Table 29: Incident cases of CML in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 30: Age-specific incident cases of CML in the US, Japan, and five major EU markets, by country, 2016
  • Table 31: Gender-specific incident cases of CML in the US, Japan, and five major EU markets, by country, 2016
  • Table 32: Total incident cases of CML in the US, Japan, and five major EU markets by phase at diagnosis and country, 2016
  • Table 33: Validation of forecast estimates against benchmark estimates
  • Table 34: Key marketed drugs for CML
  • Table 35: Bosulif drug profile
  • Table 36: Bosulif pivotal trial data in CML
  • Table 37: Bosulif late-phase trial data in CML
  • Table 38: Gleevec drug profile
  • Table 39: Gleevec pivotal trial data in CML
  • Table 40: Gleevec late-phase trial data in CML
  • Table 41: Iclusig drug profile
  • Table 42: Iclusig pivotal trial data in CML
  • Table 43: Iclusig late-phase trial data in CML
  • Table 44: Iclusig ongoing late-phase clinical trials in CML
  • Table 45: Sprycel drug profile
  • Table 46: Sprycel pivotal trial data in CML
  • Table 47: Sprycel ongoing late-phase trial in CML
  • Table 48: Sprycel and Tasigna trial data in first-line CML
  • Table 49: Synribo drug profile
  • Table 50: Synribo pivotal trial data in CML
  • Table 51: Tasigna drug profile
  • Table 52: Tasigna pivotal trial data in CML
  • Table 53: Tasigna late-phase trial data in CML
  • Table 54: Phase III pipeline products in development for CML
  • Table 55: Survival rates, disease incidence, and drug development status of various hematologic cancers
  • Table 56: Gleevec drug profile
  • Table 57: Gleevec pivotal trial data in CML
  • Table 58: Asciminib drug profile
  • Table 59: Asciminib Phase III trial in CML
  • Table 60: Asciminib early-phase trial data in CML
Back to Top